Sanofi-Regeneron’s Dupixent gets FDA’s nod for skin condition Reuters Apr 21, 2025 FDA clears Dupixent for chronic spontaneous urticaria in patients aged 12 and above, expanding its use in immune-related skin…
Granules Pharmaceuticals gains U.S. FDA approval for Lisdexamfetamine Dimesylate chewable tablets EP News Bureau Dec 17, 2024 New approval supports treatment for ADHD and binge eating disorder while addressing critical drug shortages
